ClinVar Miner

Submissions for variant NM_004168.4(SDHA):c.1551+1G>A

dbSNP: rs759806010
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001041775 SCV001205412 likely pathogenic Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 2023-10-09 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 11 of the SDHA gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in the gain of 8 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. This variant is present in population databases (rs759806010, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SDHA-related conditions. ClinVar contains an entry for this variant (Variation ID: 839910). Studies have shown that disruption of this splice site results in the activation of a cryptic splice site in intron 11 (Invitae). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Ambry Genetics RCV003160278 SCV003904157 uncertain significance Hereditary cancer-predisposing syndrome 2023-01-11 criteria provided, single submitter clinical testing The c.1551+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 11 of the SDHA gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in a transcript predicted to lead to a protein with an in-frame insertion of 8 amino acids; however, the exact functional impact of the inserted amino acids is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.